Seeking Alpha

MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • CytRx Corp. (CYTR) Appoints Shanta Chawla, M.D. As Vice President Of Clinical Development 0 comments
    Jan 16, 2014 2:41 PM | about stocks: CYTR

    Today before the opening bell, CytRx reported that it has appointed Dr. Shanta Chawla as its Vice President of Clinical Development. Dr. Chawla brings to CytRx more than 13 years of experience in clinical research, operations, and development, with an orientation toward oncology therapeutics. She will be assisting with the management of global Phase 3 clinical trial that will examine aldoxorubicin as a second-line treatment for soft tissue sarcomas.

    "In this new position, Dr. Chawla will play a key role in the management of our upcoming global Phase 3 clinical trial under a Special Protocol Assessment with aldoxorubicin as a second-line treatment for soft tissue sarcomas," said CytRx Executive Vice President and Chief Medical Officer Dr. Daniel Levitt. "She has designed and managed large clinical trials in North America and Europe for a range of cancer types, and brings to CytRx a proven ability to meet enrollment targets and work within budget requirements. We are fortunate to have Dr. Chawla join our team as we move into a very exciting and demanding phase of activity."

    "I am delighted to be joining CytRx at this critical point in the company's development, and in particular in light of the recently announced highly positive results from the global Phase 2b trial with aldoxorubicin in advanced soft tissue sarcomas," said Dr. Chawla. "I look forward to playing a significant role in the continued development of this promising oncology therapeutic."

    Dr. Chawla attained her medical doctor degree from Maulana Azad Medical College in New Delhi. She performed her internship and residency in Philadelphia at Albert Einstein Medical Center and Thomas Jefferson University Hospital, respectively. Holding a board certification, Dr. Chawla spent 2001 to 2013 at Spectrum Pharmaceuticals, at which she most recently served as Vice President of Clinical Research and Development. In that capacity, she specialized in selection of clinical trial sites and principal investigators, establishment of protocols with the FDA and key opinion leaders, preparation of FDA filings, and project team management, among other functions she performed aptly.

    Dr. Shanta Chawla is not related to Dr. Sant Chawla, the principal investigator in CytRx's global Phase 3 clinical trial for soft tissue sarcoma. As a cancer that arises in muscle tissue, fat, blood vessels, tendons, fibrous tissues, and connective tissue, soft tissue sarcoma was diagnosed in 11,400 new cases in the United States and identified as being responsible for 4,400 deaths in the United States. Over 50 types of soft tissue sarcoma have been found to exist, and this cancer can afflict the body at any age.

    For more information, visit: cytrx.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: CYTR
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.